The US Food and Drug Administration (FDA) has issued a warning letter on 14 April to New Life Pharma, identifying significant current good manufacturing practice (CGMP) violations.
The warning letter places particular emphasis on failures in aseptic processing and cleanroom control systems of the New Life Pharma facility in Northvale, New Jersey.
According to the agency, inspection findings revealed that the manufacturer lacked “the fundamental controls necessary to ensure the sterility” of its drug products, including sterile multi-dose vials of semaglutide and tirzepatide, which are injections for type 2 diabetes and chronic weight management.
Issues with cleanroom design and performance
The FDA highlighted multiple deficiencies directly linked to cleanroom performance and aseptic assurance.
These included inadequate facility and process design, with the agency noting shortcomings in cleanroom layout, filling equipment configuration, and protection of critical ISO Class 5 areas.
The warning letter also pointed to the absence of appropriate written procedures to prevent microbiological contamination, alongside insufficient validation of sterile manufacturing conditions.
High levels of manual intervention during setup and filling operations were identified as additional risk factors, increasing the likelihood of contamination events and undermining the ability to maintain controlled aseptic conditions.
Quality system and oversight failures
Beyond physical cleanroom deficiencies, the FDA cited systemic weaknesses in the company’s pharmaceutical quality system.
Inspectors found that the quality unit did not exercise adequate authority or oversight to ensure compliance with CGMP requirements or product quality standards.
The agency further stated that management oversight was insufficient, contributing to a lack of effective contamination control strategy and failure to implement essential sterile manufacturing safeguards.
Company denying inspection access
During the February 2026 inspection, the company denied FDA investigators access to parts of the manufacturing facility, actions the agency said violated regulations prohibiting the limitation or refusal of inspections.
In addition, products manufactured at the site were cited as unapproved and misbranded, with the firm failing to properly register and list its drugs with the FDA.
Production halt and product recall
Following the inspection, New Life Pharma agreed to cease drug production, although subsequent correspondence indicated the halt was temporary pending corrective actions.
During a 19 February teleconference, the FDA stated that, given the extent of deficiencies, the company should not resume manufacturing at the facility.
They recommended removing any batches of the GLP-1 drug products currently in distribution in the US market.
On 25 February, New Life Pharma initiated a voluntary recall of semaglutide and tirzepatide injectable products due to a lack of sterility assurance.
What is next?
The FDA concluded that the firm’s response to earlier inspection observations was inadequate, citing a lack of evidence demonstrating effective corrective actions or sustainable cGMP compliance.
The warning letter requires the company to respond within 15 working days, detailing corrective measures and timelines, and to address how it will prevent recurrence of the identified violations.